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A B S T R A C T
Background: An outbreak of COVID-19 in Iran has spread throughout the country. Identifying the epidemiolo-
gical characteristics of this disease will help to make appropriate decisions and thus control the epidemic. The
aim of this study was characterization of the epidemiological features of COVID-19 in Iran.
Methods: In this retrospective study, data related to the epidemiological characteristics of COVID-19 patients
admitted to Baqiyatallah Hospital in Tehran, Iran, from 19 February 2020 to 15 April 2020 have been analyzed
and reported. Patient characteristics including age, gender and underlying diseases were investigated. Data were
collected through patient records. Sex ratio, Case Fatality Rate (CFR) and daily trend of cases were also de-
termined. A multiple logistic regression analysis was also performed to assess affecting factors on mortality.
Results: From February 19, 2020 to April 15, 2020, 12870 patients referred to the hospital emergency depart-
ment, of which 2968 were hospitalized with COVID-19 diagnosis. The majority of cases were in the age group of
50 to 60 years of old. The male-to-female ratio was 1.93:1. A total of 239 deaths occurred among all cases for an
overall CFR of 1.85% based on the total number of patients (both outpatient and inpatient) and 8.06% among
hospitalized patients. Out of all patients 10.89% had comorbidity. Diabetes, chronic respiratory diseases, hy-
pertension, cardiovascular diseases, chronic Kidney diseases and cancer were the most common comorbidities
with 3.81, 2.02 , 1.99 , 1.25, 0.60 and 0.57 %, respectively. Male gender (OR=1.45, 95% CI: 1.08-1.96), older
age (OR=1.05, 95% CI: 1.04-1.06) and having underlying diseases (OR=1.53, 95% CI: 1.04-2.24) were sig-
nificantly associated with mortality.
Conclusions: The results of this study showed that Male gender, older age and having comorbidities were sig-
nificantly associated with the risk of death among COVID-19 patients. It is important to pay special attention to
male elderly patients with underlying diseases.
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1. Background
For the first time in late December 2019, cases of pneumonia with
an unknown cause were reported in Wuhan, China, and later in January
2020, a new type of coronavirus was identified as the cause of those
pneumonia cases [1]. The World Health Organization (WHO) chose the
official name of COVID- 19 (stand for coronavirus disease 2019), for the
disease, as well as the term SARS−COV-2(severe acute respiratory
syndrome coronavirus 2) for the virus [2]. A similar to SARS and
Middle East Respiratory Syndrome (MERS) coronaviruses trend has
been seen in the epidemiology of this emerging disease [3]. In March
11, 2020, the WHO announced COVID-19 as a pandemic [4]. The dis-
ease is highly contagious and each infected person could infect at least
3 other people on average [5]. As of, April 15, 2020, 76,389 patients
with COVID- 19 have been identified in Iran, of which 4777 deaths have
been occurred by the virus. According to statistics, Iran ranks sixth after
the United States, Italy, Spain, France and the United Kingdom in the
number of deaths due to COVID- 19 [6]. The first deaths from COVID-
19 reported officially on Feb 19, 2020 [7]. Identifying the epidemio-
logical characteristics of this disease will help to make appropriate
decisions and thus control the epidemic. Certain epidemiological fea-
tures of COVID-19 have been previously reported [8–11]. However,
these studies were based on relatively small sample sizes, and mostly
from China. The aim of this study was characterization of the epide-
miological features of COVID-19 in Iran as a country with a population
of more than 83 million people [12] in the Middle East and the Persian
Gulf region. Here, we report the results of an epidemiological analysis
of all cases hospitalized in Baqiyatallah Hospital, affiliated to Baqiya-
tallah University of Medical Sciences (BMSU), in Tehran, Iran.
2. Method
2.1. Study design and data collection
The present study was a retrospective, epidemiological study that
has been performed on hospitalized cases of COVID-19 in Baqiyatallah
hospital in Tehran. According to hospital data, patients were admitted
from 19 February 2020, to 15 April 2020. All patient information is
kept confidential. Patients were confirmed by RT-PCR (Reverse tran-
scription-polymerase chain reaction) using throat and nose swab spe-
cimens from the upper respiratory tract or clinically diagnosed based on
lung imaging features specially Chest CT(Computed tomography) scan
ground glass pathognomonic features consistent with coronavirus
pneumonia, depending on the physician's orders. All registered cases at
the hospital had a national unique code, so there were no duplicates.
The study variables were as follows: gender, age, final outcome (in-
cluding death or survival), type of comorbidities.
2.2. Statistical analysis
Descriptive analyses of the variables were expressed as mean
(± Standard Deviation= SD), median (with an interquartile
range= IQR=Q1-Q3), or number (%). The analyses were based on
non-missing data, and missing data were not imputed. The age and sex
distribution were examined and relevant charts were drawn. Sex ratio
(male to female) and the case fatality rate (CFR) were calculated. To
investigate the effect of age, gender, and comorbidities on mortality, a
multiple logistic regression model was used. Adjusted Odds Ratio (OR)
with 95 % Confidence Interval (CI) was calculated. The α: 0.05 was
considered as a significance level. The data were analyzed using the
STATA version 11.0 and Excel version 2010.
3. Results
From February 19, 2020 to April 15, 2020, a total of 12,870 patients
referred to the hospital emergency department, of which 2968 were
hospitalized with COVID-19 diagnosis. The mean of age was
55.50 ± 15.15 years and the median of age was 56(46–65) years. The
majority of cases were in the age group of 50–60 years (Fig. 1). Also,
most cases (66 %) were male. The male-to-female ratio was 1.93:1.
CFRs are shown in Table 1. Totally 239 deaths occurred during the
entire study period, so the overall CFR was calculated to be 1.85 %
based on the total number of patients (both outpatient and inpatient)
and also CFR was calculated to be 8.06 % among hospitalized patients.
Among the 239 deaths, the mean of age was 65.38 ± 13.67 years
and the median of age was 65(57–75) years. A majority (160= 66.94
%) were ≥60 years of age and 38(15.89 %) had comorbidities. Patients
over 80 years of age had the highest CFR among the age groups (19.27
%). The CFR was 8.54 % and 7.13 % for men and women, respectively.
A total of 323(10.89 %) of patients had chronic underlying diseases. As
shown in Fig. 2, Diabetes, chronic respiratory diseases, hypertension,
cardiovascular diseases, chronic kidney diseases and cancer were the
Fig. 1. The distribution of all cases and deaths in each age group (n= 2964).
Table 1
Demographics and characteristics of patients infected with COVID-19.
Variable Subgroups All Cases N (%) Deaths, N Case
Fatality
Rate (%)
Overall – 2964 239 8.06
Age, years 0–10 2(0.07) 0 –
10–20 8(0.27) 0 –
20–30 97(3.27) 1 1.03
30–40 416(14.03) 11 2.64
40–50 452(15.25) 13 2.87
50–60 825(27.83) 54 6.54
60–70 622(20.98) 71 11.41
70–80 350 (11.80) 52 14.85
≥80 192(6.50) 37 19.27
Gender Female 1009(34.00) 72 7.13
Male 1955(66.00) 167 8.54
Comorbidity No 2641(89.10) 201 7.61











Cancer (any) 17(0.57) 1 5.88




Recovery 2639(89.03) – –
Hospitalized 86(2.90) – –
Death 239(8.06) – –
* Other diseases: Liver disorders, chronic rheumatic diseases, Anemia,
Immunodeficiency disorders.
† Recovery refers to patients who have recovered and been discharged.
Hospitalized patients are patients who are still hospitalized and under care.
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most common comorbidities with 3.81, 2.02, 1.99, 1.25, 0.60 and 0.57
%, respectively. While patients who reported no comorbidity had a CFR
of 7.61 %, patients with comorbid conditions had higher rates (9.73 %
for diabetes, 10.81 % for those with cardiovascular disease, 15 % for
those with chronic respiratory disease, and 13.55 % for those with
hypertension, 16.66 % for chronic Kidney diseases and 5.88 % for pa-
tients with cancer. Fig. 3 indicates the number of cases as well as deaths
based on the date of admission from February 19, 2020 to April 15,
2020. The results of logistic regression showed that male gender sig-
nificantly increased odds of death by 45 % (OR=1.45, 95 % CI:
1.08–1.96). Also, for a one-year increase in the age, the odds of death
increases by 5% (OR=1.05, 95 % CI: 1.04–1.06). Having underlying
disease also increases the odds of mortality by 53 % (OR=1.53, 95 %
CI: 1.04–2.24) this was also statistically significant (Table 2).
4. Discussion
The present epidemiological study on 2964 COVID-19 hospitalized
cases between 19 February 2020 to 15 April 2020, provides information
about the disease and the outbreak in Iran. As shown in Fig. 1, the
increasing trend of hospitalized cases over a short period of time (19
February to March 11) is clear. This finding could confirm the rapid
spread of the disease in the population. The peak of hospitalization
occurred on March 11, and since March 17, the number of hospitalized
cases has decreased slightly. The data appear to indicate a propagated
source pattern of spread. Estimates suggest that around 14 % of people
infected with COVID-19 have severe disease, and 6% are critically ill
[13], hence, about 20 % of all cases of the disease are usually need to be
hospitalized. Since Baqiyatallah Hospital is a referral center in Tehran,
so, it can be concluded that there is probably a similar trend in the
general population. Among the 239 deaths, a majority (160= 66.94 %)
has been ≥60 years of age and 38(15.89 %) had comorbidities such as
diabetes, hypertension and chronic respiratory diseases and etc. Ac-
cording to the results of our study, overall CFR was calculated to be
1.85 % based on the total number of patients (both outpatient and in-
patient). Other studies have been reported CFR ranged from 2.5 % to
3%, [14,15]. CFR was also calculated to be 8.06 % among hospitalized
patients, it is not surprising that the CFR among hospitalized patients
was high as patients with a better general condition who were not
hospitalized and therefore not included in the denominator. A recently
published systematic review and meta-analysis reports a CFR of over 13
% in 7 studies describing 632 hospitalized patients [16]. Also, two
studies from China, reported a CFR of 15 % [8]and 11 % [9], respec-
tively. Besides, in a study the CFR has been reported to be as high as 49
% among critical hospitalized cases [17]. The results of logistic re-
gression showed the significant effects of age, male gender and un-
derlying diseases on risk of death in patients with COVID-19. In line
with other studies [18,19] the regression analysis in our study revealed
that older age is associated with higher risk of mortality. Some studies
showed that older age is associated with declined immune system
ability [20]. Previously, older age has been reported as an associated
factor for mortality in SARS [21] and MERS [22]. The present study
showed that male gender significantly increases mortality (OR=1.45,
95 % CI: 1.08–1.96). We also observed a greater number of males than
females in the 2964 cases of COVID-19 infection. MERS-CoV and SARS-
CoV have also been found to infect more men than women [23,24]. This
finding is consistent to other studies [9,25]. The less susceptibility to
infection among women could be attributed to the X chromosome and
sex hormones, which have been reported to play role in innate and
adaptive immunity [26]. Furthermore, according to our results, 10.89
% of patients had chronic underlying diseases, mainly diabetes, chronic
respiratory diseases, hypertension and cardiovascular diseases; this is
similar to MERS-CoV [24]. In line with other studies [27–29], our result
also showed that, having comorbidities had a statistically significant
effect on Mortality (OR=1.53, 95 % CI: 1.04–2.24). A study suggested
that compared to patients with no comorbidities, the risk of death in
patients with influenza is more than in those who had cardiovascular
disease and hypertension [30]. As far as our knowledge shows, the
present study is the first descriptive study of the COVID-19 outbreak in
Iran, with a large sample size. Although the sample size in the present
study is a major advantage, unfortunately, more detailed patient in-
formation, particularly regarding clinical outcomes and early symptoms
was unavailable at the time of analysis. Importantly, this may limit the
conclusions from this data. However, the data in this study permit an
early assessment of the epidemiological characteristics of COVID-19
cases in Tehran, Iran. Further studies in outpatient, primary care, or
community settings would help to get a full picture of the clinical
presentation, natural history, risk factors and the spectrum of clinical
severity of the disease. In addition, further efforts should be made to
compensate for the above mentioned limitation in future studies. Rapid,
reliable and feasible diagnostic tests are important, as well as differ-
ential diagnoses based on clinical descriptions by physicians. Careful
national surveillance is essential to monitor the disease and its epide-
miological characteristics including infectivity, host adaption, viral
evolution, transmissibility, and pathogenicity. Efforts and initiatives at
the national, regional and global levels need to be made to cut off the
disease transmission chain.
Fig. 2. The distribution of comorbidities among all Covid-19 cases as well as
cases that have died.
Fig. 3. The distribution of Covid-19 patients according to date of Hospital ad-
mission (n= 2964).
Table 2





P-Value [95 % Confidence
Interval]
Comorbidity 1.53 0.19 0.03 1.04 - 2.24
Age 1.05 0.005 < 0.0001 1.04 - 1.06
Male Gender 1.45 0.15 0.01 1.08 - 1.96
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5. Conclusion
The results of this study emphasize the significant effect of older
age, male gender and underling diseases on the risk of mortality among
COVID-19 patients, which has been mentioned previously in other
studies. So it is recommended to take preventative measures more
seriously in the elderly patients. Also regarding medical care, it is im-
portant to pay special attention to elderly patients who also have un-
derlying diseases. As COVID-19 is considered a global health threat, it
still needs to be investigated deeply.
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